Loading...
•
Jun 30, 2023
Carisma Therapeutics Q2 2023 Earnings Report
Reported financial results for the second quarter of 2023 and highlighted recent business updates.
Key Takeaways
Carisma Therapeutics reported its Q2 2023 financial results, highlighting the dosing of the first patient in the Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® and the nomination of an additional oncology target as part of the collaboration with Moderna. The company's cash, cash equivalents, and marketable securities of $117.1 million are expected to fund operations through 2024.
Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® in patients with HER2-overexpressing solid tumors.
Nominated additional oncology target as part of the Company’s collaboration with Moderna to develop in-vivo targeted CAR-M therapies.
Cash, cash equivalents and marketable securities of $117.1 million expected to fund company through 2024.
The Phase 1 clinical trial is first-of-its-kind, marking the first time that engineered macrophages are being studied in humans.
Forward Guidance
Carisma believes that its cash, cash equivalents and marketable securities of $117.1 million as of June 30, 2023, are sufficient to sustain Carisma's planned operations through the end of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...